Endothelin, kidney disease, and hypertension

Hypertension

Volumn 61, Issue 6, 2013, Pages 1142-1145

  Speed, Joshua S ^a   Pollock, David M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR;

ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; HUMAN; HYPERTENSION; KIDNEY CORTEX; KIDNEY DISEASE; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; SEX DIFFERENCE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ENDOTHELINS; HUMANS; HYPERTENSION; KIDNEY DISEASES; RECEPTORS, ENDOTHELIN;

EID: 84878913517     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.00595     Document Type: Article

References (47)

1. Capone C, Faraco G, Coleman C, Young CN, Pickel VM, Anrather J, Davisson RL, Iadecola C. Endothelin 1-dependent neurovascular dysfunction in chronic intermittent hypoxia. Hypertension. 2012; 60: 106-113.
2. Bruno RM, Sudano I, Ghiadoni L, Masi L, Taddei S. Interactions between sympathetic nervous system and endogenous endothelin in patients with essential hypertension. Hypertension. 2011; 57: 79-84.
3. Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, van den Meiracker AH, Merkus D. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012; 59: 151-157.
4. Kappers MtHW, Smedts FMM, Horn T, van Esch JHM, Sleijfer S, Leijten F, Wesseling S, Strevens H, Jan Danser AH, van den Meiracker AH. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011; 58: 295-302.
5. Meens MJ, Mattheij NJ, Nelissen J, Lemkens P, Compeer MG, Janssen BJ, De Mey JG. Calcitonin gene-related peptide terminates long-lasting vasopressor responses to endothelin 1 in vivo. Hypertension. 2011; 58: 99-106.
6. Kittikulsuth W, Pollock JS, Pollock DM. Sex differences in renal medullary endothelin receptor function in angiotensin II hypertensive rats. Hypertension. 2011; 58: 212-218.
7. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011; 57: 772-779.
8. Dhaun N, Webb DJ. Dual endothelin-converting enzyme/neutral endopeptidase inhibition. Hypertension. 2011; 57: 667-669.
9. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr, Ryan MJ, Dechend R. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension. 2009; 54: 905-909.
10. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, Kedzierski RM, Hammer RE, Yanagisawa H, Williams SC, Richardson JA, Suzuki T, Yanagisawa M. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension. 2010; 56: 121-128.
11. George EM, Granger JP. Linking placental ischemia and hypertension in preeclampsia. Hypertension. 2012; 60: 507-511.
12. Chen DD, Dong YG, Yuan H, Chen AF. Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension. 2012; 59: 1037-1043.
13. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures. Hypertension. 2010; 56: 824-830.
14. Raichlin E, Prasad A, Mathew V, Kent B, Holmes DR Jr, Pumper GM, Nelson RE, Lerman LO, Lerman A. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension. 2008; 52: 522-528.
15. Liang F, Yang S, Yao L, Belardinelli L, Shryock J. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. Hypertension. 2012; 59: 705-711.
16. Elmarakby AA, Loomis ED, Pollock JS, Pollock DM. NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1. Hypertension. 2005; 45: 283-287. (Pubitemid 40179973)
17. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010; 56: 942-949.
18. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 2011; 91: 1-77.
19. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010; 55: 394-398.
20. LaMarca B, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K, Granger JP. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension. 2008; 52: 1161-1167.
21. Loria AS, Pollock DM, Pollock JS. Early life stress sensitizes rats to angiotensin II-induced hypertension and vascular inflammation in adult life. Hypertension. 2010; 55: 494-499.
22. Lob HE, Marvar PJ, Guzik TJ, Sharma S, McCann LA, Weyand C, Gordon FJ, Harrison DG. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension. 2010; 55: 277-83, 6p following 283.
23. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension. Hypertension. 2011; 57: 132-140.
24. Kennedy DJ, Chen Y, Huang W, Viterna J, Liu J, Westfall K, Tian J, Bartlett DJ, Tang WH, Xie Z, Shapiro JI, Silverstein RL. CD36 and Na/K-ATPase-?1 form a proinflammatory signaling loop in kidney. Hypertension. 2013; 61: 216-224.
25. Speed JS, George EM, Arany M, Cockrell K, Granger JP. Role of 20-hydroxyeicosatetraenoic acid in mediating hypertension in response to chronic renal medullary endothelin type B receptor blockade. PLoS One. 2011; 6: e26063.
26. Ahn D, Ge Y, Stricklett PK, Gill P, Taylor D, Hughes AK, Yanagisawa M, Miller L, Nelson RD, Kohan DE. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004; 114: 504-511. (Pubitemid 39572100)
27. Speed JS, LaMarca B, Berry H, Cockrell K, George EM, Granger JP. Renal medullary endothelin-1 is decreased in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2011; 301: R519-R523.
28. Sullivan JC, Bhatia K, Yamamoto T, Elmarakby AA. Angiotensin (1-7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats. Hypertension. 2010; 56: 658-666.
29. Ojeda NB, Hennington BS, Williamson DT, Hill ML, Betson NE, Sartori-Valinotti JC, Reckelhoff JF, Royals TP, Alexander BT. Oxidative stress contributes to sex differences in blood pressure in adult growthrestricted offspring. Hypertension. 2012; 60: 114-122.
30. Sartori-Valinotti JC, Iliescu R, Yanes LL, Dorsett-Martin W, Reckelhoff JF. Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked. Hypertension. 2008; 51: 1170-1176. (Pubitemid 351398978)
31. Nakano D, Pollock DM. Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension. 2009; 53: 324-330.
32. Sasser JM, Pollock JS, Pollock DM. Renal endothelin in chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol. 2002; 283: R243-R248. (Pubitemid 34863930)
33. Reckelhoff JF, Zhang H, Srivastava K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the reninangiotensin system. Hypertension. 2000; 35(1 Pt 2): 480-483. (Pubitemid 30054220)
34. Dhaun N, Johnston NR, Goddard J, Webb DJ. Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease. Hypertension. 2011; 58: e11-e12.
35. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010; 21: 527-535.
36. LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension. 2008; 51: 982-988. (Pubitemid 351398991)
37. Roberts L, LaMarca BB, Fournier L, Bain J, Cockrell K, Granger JP. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension. 2006; 47: 615-618. (Pubitemid 43843885)
38. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008; 294: H541-H550. (Pubitemid 351253261)
39. Abdalvand A, Morton JS, Bourque SL, Quon AL, Davidge ST. Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow. Hypertension. 2013; 61: 488-493.
40. Tam Tam KB, George E, Cockrell K, Arany M, Speed J, Martin JN Jr, Lamarca B, Granger JP. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol. 2011; 204: 330.e1-330.e4.
41. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374: 1423-1431.
42. Kassab S, Miller MT, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension. 1998; 31(1 Pt 2): 397-402.
43. D'Angelo G, Loria AS, Pollock DM, Pollock JS. Endothelin activation of reactive oxygen species mediates stress-induced pressor response in Dahl salt-sensitive prehypertensive rats. Hypertension. 2010; 56: 282-289.
44. Williams JM, Zhao X, Wang MH, Imig JD, Pollock DM. Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension. 2005; 46: 366-371. (Pubitemid 41099171)
45. Smith WE, Kane AV, Campbell ST, Acheson DW, Cochran BH, Thorpe CM. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun. 2003; 71: 1497-1504. (Pubitemid 36254337)
46. Lima VV, Giachini FR, Carneiro FS, Carneiro ZN, Saleh MA, Pollock DM, Fortes ZB, Carvalho MH, Ergul A, Webb RC, Tostes RC. O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1 Hypertension. 2010; 55: 180-188.
47. Taylor TA, Gariepy CE, Pollock DM, Pollock JS. Gender differences in ET and NOS systems in ETB receptor-deficient rats: effect of a high salt diet. Hypertension. 2003; 41(3 Pt 2): 657-662. (Pubitemid 36314570)